Literature DB >> 30209582

Total spondylectomy for Enneking stage III giant cell tumor of the mobile spine.

Noriaki Yokogawa1, Hideki Murakami2, Satoru Demura1, Satoshi Kato1, Katsuhito Yoshioka1, Takaki Shimizu1, Norihiro Oku1, Ryo Kitagawa1, Hiroyuki Tsuchiya1.   

Abstract

PURPOSE: We reported the surgical outcomes of total en bloc spondylectomy (TES) with intralesional T-saw transpedicular osteotomy in patients with Enneking stage III spinal giant cell tumors (GCTs).
METHODS: The medical records and imaging and pathological studies of 25 consecutive patients with Enneking stage III spinal GCTs undergoing surgery at our institution who were followed for at least 2 years were retrospectively reviewed.
RESULTS: Eight men and 17 women (mean age: 34.2 years, range 16-51 years, at the time of surgery) were included. Six patients underwent previous tumor excision at another hospital, and one patient had a history of denosumab treatment. The GCTs were at the cervical, thoracic, and lumbar levels in three, nine, and 13 patients, respectively. TES was performed in 13 patients; 12 required intralesional pediculotomy. The remaining patients underwent total piecemeal spondylectomy with further intralesional tumor resection. During a mean follow-up of 99.2 months (range 24-216), two patients who underwent total piecemeal spondylectomy had local tumor recurrence, but no patients who underwent TES with intralesional pediculotomy had recurrence. The 2- and 10-year recurrence-free survival rates of patients treated with total piecemeal spondylectomy were 91.7% and 78.6%, respectively, while those of patients treated with TES were both 100%.
CONCLUSIONS: TES with intralesional pediculotomy had a good surgical outcome even in patients with Enneking stage III spinal GCT, suggesting that minimal intralesional procedures could radically cure spinal GCTs. These slides can be retrieved under Electronic Supplementary Material.

Entities:  

Keywords:  Giant cell tumor; Mobile spine; Total en bloc spondylectomy; Total piecemeal spondylectomy; Tumor resection

Mesh:

Year:  2018        PMID: 30209582     DOI: 10.1007/s00586-018-5761-3

Source DB:  PubMed          Journal:  Eur Spine J        ISSN: 0940-6719            Impact factor:   3.134


  26 in total

1.  Giant cell tumor: rapid recurrence after cessation of long-term denosumab therapy.

Authors:  George R Matcuk; Dakshesh B Patel; Aaron J Schein; Eric A White; Lawrence R Menendez
Journal:  Skeletal Radiol       Date:  2015-02-26       Impact factor: 2.199

2.  Giant cell tumor of the mobile spine: a review of 49 cases.

Authors:  Stefano Boriani; Stefano Bandiera; Roberto Casadei; Luca Boriani; Rakesh Donthineni; Alessandro Gasbarrini; Elettra Pignotti; Roberto Biagini; Joseph H Schwab
Journal:  Spine (Phila Pa 1976)       Date:  2012-01-01       Impact factor: 3.468

3.  Giant cell tumor of the thoracic spine completely removed by total spondylectomy after neoadjuvant denosumab therapy.

Authors:  Noritaka Yonezawa; Hideki Murakami; Satoshi Kato; Akihiko Takeuchi; Hiroyuki Tsuchiya
Journal:  Eur Spine J       Date:  2017-04-10       Impact factor: 3.134

4.  Factors affecting prognosis of patients with giant cell tumors of the mobile spine: retrospective analysis of 102 patients in a single center.

Authors:  Wei Xu; Xiang Li; Wending Huang; Yu Wang; Shuai Han; Su Chen; Leqin Xu; Xinghai Yang; Tielong Liu; Jianru Xiao
Journal:  Ann Surg Oncol       Date:  2012-10-25       Impact factor: 5.344

5.  Giant-cell tumor of bone.

Authors:  M Campanacci; N Baldini; S Boriani; A Sudanese
Journal:  J Bone Joint Surg Am       Date:  1987-01       Impact factor: 5.284

6.  Giant cell tumor of the cervical spine: a series of 22 cases and outcomes.

Authors:  Ma Junming; Yang Cheng; Cao Dong; Xiao Jianru; Yang Xinghai; Huang Quan; Zheng Wei; Yang Mesong; Feng Dapeng; Yuan Wen; Ni Bin; Jia Lianshun; Liu Huimin
Journal:  Spine (Phila Pa 1976)       Date:  2008-02-01       Impact factor: 3.468

7.  Giant cell tumor of bone: treatment and outcome of 214 cases.

Authors:  Maurice Balke; Laura Schremper; Carsten Gebert; Helmut Ahrens; Arne Streitbuerger; Gabriele Koehler; Jendrik Hardes; Georg Gosheger
Journal:  J Cancer Res Clin Oncol       Date:  2008-03-06       Impact factor: 4.553

8.  Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone.

Authors:  Piotr Rutkowski; Stefano Ferrari; Robert J Grimer; Paul D Stalley; Sander P D Dijkstra; Andrzej Pienkowski; Gualter Vaz; Jay S Wunder; Leanne L Seeger; Amy Feng; Zachary J Roberts; Bruce A Bach
Journal:  Ann Surg Oncol       Date:  2015-06-02       Impact factor: 5.344

Review 9.  Systematic Review and Meta-analysis of En Bloc Vertebrectomy Compared with Intralesional Resection for Giant Cell Tumors of the Mobile Spine.

Authors:  Panya Luksanapruksa; Jacob M Buchowski; Weerasak Singhatanadgige; David B Bumpass
Journal:  Global Spine J       Date:  2016-03-07

10.  Recurrence of Giant Cell Tumor of the Spine after Resection: A Report of 10 Cases.

Authors:  Peng Lin; Nong Lin; Wangsiyuan Teng; Sheng-Dong Wang; Wei-Bo Pan; Xin Huang; Xiao-Bo Yan; Meng Liu; Heng-Yuan Li; Bing-Hao Li; Ling-Ling Sun; Zhan Wang; Xing-Zhi Zhou; Zhao-Ming Ye
Journal:  Orthop Surg       Date:  2018-05       Impact factor: 2.071

View more
  9 in total

1.  Subtotal En Bloc Resection of the Fourth Lumbar Vertebra for Giant Cell Tumor Using Combined Posterior and Lateral Retroperitoneal Approach.

Authors:  Kosei Ono; Bungo Otsuki; Shunsuke Fujibayashi; Takayoshi Shimizu; Koichi Murata; Shuichi Matsuda
Journal:  Spine Surg Relat Res       Date:  2021-01-12

2.  A Multiparametric Method Based on Clinical and CT-Based Radiomics to Predict the Expression of p53 and VEGF in Patients With Spinal Giant Cell Tumor of Bone.

Authors:  Qizheng Wang; Yang Zhang; Enlong Zhang; Xiaoying Xing; Yongye Chen; Ke Nie; Huishu Yuan; Min-Ying Su; Ning Lang
Journal:  Front Oncol       Date:  2022-06-21       Impact factor: 5.738

Review 3.  Diagnosis and Treatment of Lumbar Giant Cell Tumor of the Spine: Update on Current Management Strategies.

Authors:  Andrew R Leggett; Ari R Berg; Heidi Hullinger; Joseph B Benevenia
Journal:  Diagnostics (Basel)       Date:  2022-03-30

4.  Prediction of the early recurrence in spinal giant cell tumor of bone using radiomics of preoperative CT: Long-term outcome of 62 consecutive patients.

Authors:  Qizheng Wang; Yang Zhang; Enlong Zhang; Xiaoying Xing; Yongye Chen; Min-Ying Su; Ning Lang
Journal:  J Bone Oncol       Date:  2021-03-16       Impact factor: 4.072

5.  Clinical Significance of Preoperative CT and MR Imaging Findings in the Prediction of Postoperative Recurrence of Spinal Giant Cell Tumor of Bone.

Authors:  Qi-Zheng Wang; En-Long Zhang; Xiao-Ying Xing; Min-Ying Su; Ning Lang
Journal:  Orthop Surg       Date:  2021-11-28       Impact factor: 2.071

Review 6.  Evaluating the Optimal Management of Inoperable Giant Cell Tumors of the Spine: A Systematic Review and Meta-Analysis.

Authors:  Paolo Palmisciano; Gianluca Ferini; Andrew L Chen; Kishore Balasubramanian; Abdurrahman F Kharbat; Navraj S Sagoo; Othman Bin Alamer; Gianluca Scalia; Giuseppe E Umana; Salah G Aoun; Ali S Haider
Journal:  Cancers (Basel)       Date:  2022-02-14       Impact factor: 6.639

7.  The Effect of Denosumab and Risk Factors for Recurrence in Spinal Giant Cell Tumors: A Systematic Review and Meta-Analysis.

Authors:  Sung Hyun Noh; Yoon Ha; Pyung Goo Cho; Keung Nyun Kim; Dong Ah Shin; Sang Hyun Kim
Journal:  Yonsei Med J       Date:  2022-09       Impact factor: 3.052

8.  Outcome of Reoperation for Local Recurrence Following En Bloc Resection for Bone Giant Cell Tumor of the Extremity.

Authors:  Shinji Tsukamoto; Andreas F Mavrogenis; Suraj Hindiskere; Kanya Honoki; Akira Kido; Hiromasa Fujii; Tomoya Masunaga; Yasuhito Tanaka; Pramod S Chinder; Davide Maria Donati; Costantino Errani
Journal:  Curr Oncol       Date:  2022-09-05       Impact factor: 3.109

9.  Revision surgery for instrumentation failure after total en bloc spondylectomy: a retrospective case series.

Authors:  Kazuya Shinmura; Satoshi Kato; Satoru Demura; Noriaki Yokogawa; Noritaka Yonezawa; Takaki Shimizu; Norihiro Oku; Ryo Kitagawa; Makoto Handa; Ryohei Annen; Hideki Murakami; Hiroyuki Tsuchiya
Journal:  BMC Musculoskelet Disord       Date:  2020-09-02       Impact factor: 2.362

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.